ClearPoint Neuro, Inc.
For the period ended Jun 30, 2026. Filed Aug 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
(a) None.
(b) None.
(c)During the quarter ended June 30, 2026, none of our officers or directors adopted orterminated a“Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K, except as follows:
On June 4, 2026, Lynnette C. Fallon, a member of our Board of Directors, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The plan's maximum duration is until December 31, 2027. The maximum number of shares to be sold under the plan is 5,256.
On June 10, 2026, Matthew Klein, a member of our Board of Directors, adopted a new Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The plan's maximum duration is until July 31, 2027. The maximum number of shares to be sold under the plan is 59,120.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.